Tango Therapeutics Inc. 公布的数据显示,其药物Vopimetostat与Daraxonrasib联合疗法的安全性特征总体良好。在临床研究中,该联合方案未引发新的安全性问题,耐受性表现符合预期。
Tango Therapeutics Inc. 公布的数据显示,其药物Vopimetostat与Daraxonrasib联合疗法的安全性特征总体良好。在临床研究中,该联合方案未引发新的安全性问题,耐受性表现符合预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.